Study of the Safety, Tolerability, Pharmacokinetics and Effect on Renal Potassium Clearance after Multiple Oral Dosing of LY2623091 in Healthy Volunteers

Completed

• Conditions: chronic kidney disease; Kidney failure; 10038430

• Registration Number: NL-OMON36630
• Lead Sponsor: Eli Lilly

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 32

Inclusion Criteria

- Healthy males and/or healthy females (postmenopausal/sterilized)
- 18-65 years, inclusive
- BMI: 19.0-32.5 kg/m2, inclusive
- non-smoking, or smoking a maximum of10 cigarettes/day

Exclusion Criteria

Suffering from: hepatitis B, cancer or HIV/AIDS. In case of participation in another drug study within 60 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1.5 liters of blood (for men) / more than 1.0 liters of blood (for women) in the 10 months prior the start of this study.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Pharmacodynamics<br /><br>Pharmacokinetics<br /><br>Safety</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>n.a.</p><br>